PURPOSE: To profile different tyrosine kinase (TK) expression patterns in clear cell renal carcinoma (ccRCC). METHODS: We analysed mRNA expression levels of 89 receptor and non-receptor TK in corresponding cancer and normal renal tissue from 5 patients with ccRCC using the TaqMan Low-Density Array technology. In order to confirm aberrant TK expressions, a subsequent analysis of 25 ccRCC and corresponding normal renal tissues was performed, applying quantitative real-time PCR. To confirm mRNA expression levels on protein level, we studied ERBB4 and HCK using immunohistochemistry. RESULTS: A total of 12 TK were significantly upregulated in ccRCC (ABL2, FLT1, BTK, HCK, JAK3, CSF1R, MET, JAK1, MATK, PTPRC, FYN and CSK), coherently 7 TK demonstrated a down-regulation (ERBB4, PDGFRA, NRTK3, SYK, ERBB2, FGFR3 and PTK7). These findings were validated by the utilization of RT-PCR for ABL2, FLT1 BTK, HCK, JAK3, CSF1R, MET, JAK1, MATK and vice versa for ERBB4 and PDGFRA. Immunohistochemistry revealed ERBB4 expression to be significantly lower in ccRCC in comparison to papillary RCC, chromophobe RCC, renal oncocytoma and normal renal tissue (P < 0.001). HCK protein expression was reduced in ccRCC in contrast to papillary RCC (P < 0.001) or oncocytoma (P = 0.023), but similar to chromphobe RCC (P = 0.470), sarcomatoid RCC (P = 0.754) and normal renal tissue (P = 0.083). Neither ERBB4 nor HCK were correlated (P > 0.05) with clinical-pathological parameters. CONCLUSION: TK constitute valuable targets for pharmaceutical anti-cancer therapy. ERBB4 and HCK depict significantly lower expression levels in renal cancer tissues.
PURPOSE: To profile different tyrosine kinase (TK) expression patterns in clear cell renal carcinoma (ccRCC). METHODS: We analysed mRNA expression levels of 89 receptor and non-receptor TK in corresponding cancer and normal renal tissue from 5 patients with ccRCC using the TaqMan Low-Density Array technology. In order to confirm aberrant TK expressions, a subsequent analysis of 25 ccRCC and corresponding normal renal tissues was performed, applying quantitative real-time PCR. To confirm mRNA expression levels on protein level, we studied ERBB4 and HCK using immunohistochemistry. RESULTS: A total of 12 TK were significantly upregulated in ccRCC (ABL2, FLT1, BTK, HCK, JAK3, CSF1R, MET, JAK1, MATK, PTPRC, FYN and CSK), coherently 7 TK demonstrated a down-regulation (ERBB4, PDGFRA, NRTK3, SYK, ERBB2, FGFR3 and PTK7). These findings were validated by the utilization of RT-PCR for ABL2, FLT1BTK, HCK, JAK3, CSF1R, MET, JAK1, MATK and vice versa for ERBB4 and PDGFRA. Immunohistochemistry revealed ERBB4 expression to be significantly lower in ccRCC in comparison to papillary RCC, chromophobe RCC, renal oncocytoma and normal renal tissue (P < 0.001). HCK protein expression was reduced in ccRCC in contrast to papillary RCC (P < 0.001) or oncocytoma (P = 0.023), but similar to chromphobe RCC (P = 0.470), sarcomatoid RCC (P = 0.754) and normal renal tissue (P = 0.083). Neither ERBB4 nor HCK were correlated (P > 0.05) with clinical-pathological parameters. CONCLUSION:TK constitute valuable targets for pharmaceutical anti-cancer therapy. ERBB4 and HCK depict significantly lower expression levels in renal cancer tissues.
Authors: Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski Journal: Oncologist Date: 2011-04-13
Authors: T A Fong; L K Shawver; L Sun; C Tang; H App; T J Powell; Y H Kim; R Schreck; X Wang; W Risau; A Ullrich; K P Hirth; G McMahon Journal: Cancer Res Date: 1999-01-01 Impact factor: 12.701
Authors: Minna K Kankuri-Tammilehto; Karl-Ove Söderström; Tarja-Terttu Pelliniemi; Tero Vahlberg; Seppo O Pyrhönen; Eeva K Salminen Journal: Anticancer Res Date: 2010-07 Impact factor: 2.480
Authors: Ossama W Tawfik; Brandan Kramer; Barbara Shideler; Marsha Danley; Bruce F Kimler; Jeffrey Holzbeierlein Journal: Arch Pathol Lab Med Date: 2007-02 Impact factor: 5.534
Authors: Orit Jacobson; Ido D Weiss; Lu Wang; Zhe Wang; Xiangyu Yang; Andrew Dewhurst; Ying Ma; Guizhi Zhu; Gang Niu; Dale O Kiesewetter; Neil Vasdev; Steven H Liang; Xiaoyuan Chen Journal: J Nucl Med Date: 2015-08-27 Impact factor: 10.057
Authors: Won-Sik Shin; Junhye Kwon; Hae Won Lee; Moon Chul Kang; Hye-Won Na; Seung-Taek Lee; Jong Ho Park Journal: Cancer Sci Date: 2013-06-13 Impact factor: 6.716
Authors: Xiang Shu; Jianchun Gu; Maosheng Huang; Nizar M Tannir; Surena F Matin; Jose A Karam; Christopher G Wood; Xifeng Wu; Yuanqing Ye Journal: Carcinogenesis Date: 2018-05-28 Impact factor: 4.944
Authors: Christina A Von Roemeling; Laura A Marlow; Derek C Radisky; Austin Rohl; Hege Ekeberg Larsen; Johnny Wei; Heather Sasinowska; Heng Zhu; Richard Drake; Maciek Sasinowski; Han W Tun; John A Copland Journal: Oncotarget Date: 2014-07-30
Authors: Pooja Ghatalia; Eddy S Yang; Brittany N Lasseigne; Ryne C Ramaker; Sara J Cooper; Dongquan Chen; Sunil Sudarshan; Shi Wei; Arjun S Guru; Amy Zhao; Tiffiny Cooper; Deborah L Della Manna; Gurudatta Naik; Richard M Myers; Guru Sonpavde Journal: PLoS One Date: 2016-08-30 Impact factor: 3.240